

9 July 2013 EMA/HMPC/320930/2012 Committee on Herbal Medicinal Products (HMPC)

# Community herbal monograph on *Melaleuca alternifolia* (Maiden and Betch) Cheel, *M. linariifolia* Smith, *M. dissitiflora* F. Mueller and/or other species of *Melaleuca*, aetheroleum

Draft

Discussion in Working Party on Community monographs and Community	May 2012
list (MLWP)	September 2012
	January 2013
	March 2013
	May 2013
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	0. 101/2 2012
for consultation	9 July 2013
End of consultation (deadline for comments). Comments should be	15 December 2013
provided using this template to hmpc.secretariat@ema.europa.eu	15 December 2013
Rediscussion in Working Party on Community monographs and	
Community list (MLWP)	
Adoption by Committee on Herbal Medicinal Products (HMPC)	

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M.
	dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum;
	Melaeucae aetheroleum; Tea tree oil



An agency of the European Union

BG (bălgarski): Чаено дърво, масло	LT (lietuvių kalba): Arbatmedžių eterinis aliejus
CS (čeština): silice kajeputu střídavolistého	LV (latviešu valoda): Tējaskoka ēteriskā eļļa
DA (dansk): Tetræolie	MT (malti): Żejt tal-Melaleucae
DE (Deutsch): Teebaumöl	NL (nederlands): Theeboomolie
EL (elliniká): Μελαλεύκης αιθέριο έλαιο	PL (polski): Olejek eteryczny drzewa
EN (English): Tea tree oil	herbacianego
ES (espanol): Melaleuca alternifolia, aceite	PT (português): Óleo esencial de melaleuca
esencial de	RO (română):
ET (eesti keel): teepuuõli	SK (slovenčina): Silica melaleuky
FI (suomi): teepuuöljy	SL (slovenščina): eterično olje melalevke
FR (français): Mélaleuca (arbre à thé) (huile	SV (svenska): Teträdsolja
essentielle de)	IS (íslenska):
HU (magyar): Teafa-olaj	NO (norsk): Tetreolje
HR (hrvatska):	
IT (italiano): Melaleuca essenza	

# Community herbal monograph on (Maiden and Betch) Cheel, *M. linariifolia* Smith, *M. dissitiflora* F. Mueller and/or other species of *Melaleuca*, aetheroleum

## 1. Name of the medicinal product

To be specified for the individual finished product.

# 2. Qualitative and quantitative composition<sup>1,2</sup>

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	<i>Melaleuca alternifolia</i> (Maiden and Betch) Cheel, <i>M. linariifolia</i> Smith, <i>M. dissitiflora</i> F. Mueller and/or other species of <i>Melaleuca</i> , aetheroleum (tea tree oil)
	i) Herbal substance
	Not applicable.
	ii) Herbal preparations
	Essential oil obtained by steam distillation from the foliage and terminal branchlets

#### 3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparation in liquid and semi-solid dosage forms for cutaneous use (indication 1-3) or in liquid dosage form for oromucosal use (indication 4).
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

<sup>&</sup>lt;sup>1</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

 $<sup>^2</sup>$  The material complies with the Ph. Eur. monograph (ref.: 01/2008: 1837).

# 4. Clinical particulars

#### 4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product for treatment of small superficial wounds and insect bites.
	Indication 2)
	Traditional herbal medicinal product for treatment of small boils (furuncles and mild acne).
	Indication 3)
	Traditional herbal medicinal product for the relief of itching and irritation in cases of mild athlete's foot.
	Indication 4)
	Traditional herbal medicinal product for symptomatic treatment of minor inflammation of the oral mucosa.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

#### 4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Indication 1)
	Adolescents, adults and elderly Liquid preparations containing 0.5% to 10% of essential oil to be applied on the affected area 1-3 times daily.
	Indication 2)
	Adolescents, adults and elderly Oily liquid or semi-solid preparations containing 10% of essential oil, to be applied on the affected area 1-3 times daily or
	0.7-1 ml of essential oil stirred in 100 ml of lukewarm water to be applied as an impregnated dressing to the affected areas of the skin.

Well-established use	Traditional use
	Indication 3)
	Adolescents, adults and elderly Oily liquid or semi-solid preparations containing 10% of essential oil, to be applied on the affected area 1-3 times daily.
	Indication 4)
	Adolescents, adults and elderly 0.17–0.33 ml of essential oil to be mixed in 100 ml of water for rinse or gargle several times daily.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Indication 1)
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 2) and 3)
	Not to be used for more than 1 month.
	If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 4)
	If the symptoms persist longer than 5 days during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Indication 1), 2) and 3)
	Cutaneous use.
	Indication 4)
	Oromucosal use.

#### 4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance or to colophonium.

#### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children under 12 years of age has not been established due to lack of adequate data.
	Not to be used orally or as inhalation. Not to be used in eyes or in ears.
	If symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 1) Not to be used on burn wounds.
	If fever or signs of exacerbating skin infection are observed, a doctor or a qualified health care practitioner should be consulted.
	Indication 2) In cases with severe acne a doctor or a qualified healthcare practitioner shall be consulted.
	Indication 3)
	For the eradication of fungal infection a doctor or a qualified healthcare practitioner shall be consulted.

# 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

#### 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

Well-established use	Traditional use
	No fertility data available.

#### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8. Undesirable effects

Well-established use	Traditional use
	Adverse skin reactions like smarting pain, mild pruritus, burning sensation, irritation, itching, stinging, erythema, oedema and allergic reactions have been reported. The frequency is not known. Burn-like skin reaction has been reported. The frequency is rare (<1/1.000). If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	Accidental poisonings following ingestion of 10-25 ml have shown that Melaleucae aetheroleum causes Central Nervous System depression and muscle weakness. However, these symptoms had generally resolved within 36 hours.

# 5. Pharmacological properties

#### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

Community herbal monograph on *Melaleuca alternifolia* (Maiden and Betch) Cheel, *M. linariifolia* Smith, *M. dissitiflora* F. Mueller and/or other species of *Melaleuca*, aetheroleum EMA/HMPC/320930/2012

#### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

#### 5.3. Preclinical safety data

Well-established use	Traditional use
	Melaleucae aetheroleum was not genotoxic in <i>in- vivo</i> mouse micronucleus test (up to 1750 mg/kg). Ames test data are incomplete. Tests on reproductive toxicity and on carcinogenicity have not been performed.

# 6. Pharmaceutical particulars

Well-established use	Traditional use
	Store in air-tight containers, protected from light and heat.
	Proper storage and handling should avoid the formation of oxidation products which have greater potential of skin sensitisation.

# 7. Date of compilation/last revision

9 July 2013